Full Paper
mesh ASTM). Reactions were monitored by TLC. Solvents were pur-
chased from Sigma, and solvents used for spectroscopy experi-
ments were of spectrophotometric grade. (Prop-2-yn-1-yloxy)ben-
zene,[1] 2,3,4-tris(prop-2-yn-1-yloxy)benzaldehyde,[1] 3,5-bis (prop-2-
yn-1-yloxy) benzaldehyde,14-(prop-2-yn-1-yloxy) benzaldehyde,[8e]
The THF/H2O ratio was 1/1 (v/v). The mixture was stirred overnight.
The solvent was then evaporated and extracted with dichlorome-
thane, and the crude product was purified by column chromatog-
raphy on silica gel (CH2Cl2) as the eluent to afford product BT1 as
a light-orange solid (95 mg, 80%). 1H NMR (400 MHz, CDCl3): d=
8.03 (s, 1H), 7.52–7.49 (d, J=11.6 Hz, 2H), 7.23–7.20 (m, 4H), 7.18–
7.11 (m, 11 H), 7.10–7.03 (m, 6H), 6.00 (s, 2H, pyrrole-H), 5.33 (s,
2H), 2.57 (s, 3H), 1.43 ppm (s, 3H); 13C NMR (100 MHz, CDCl3): d=
159.0, 155.5, 145.0, 144.5, 143.4, 143.4, 143.1, 142.6, 141.8, 139.5,
135.1, 133.2, 132.9, 131.5, 131.4, 129.9, 129.6, 128.5, 128.2, 128.1,
128.0, 127.1, 127.03, 126.98, 121.4, 121.1, 119.9, 115.7, 68.2, 25.8,
14.8 ppm (overlapping was observed for some aromatic carbon
atoms); HRMS (MALDI-TOF): m/z calcd for [BT1+H]+: 752.33722;
found: 752.35817.
[9i]
4,[18b] and TPE-N3 were synthesised according to procedures re-
ported in the literature.
Synthesis and characterisation
Compound 1: 4-(Prop-2-yn-1-yloxy)benzaldehyde, (300 mg,
1.88 mmol) and 2,4-dimethylpyrrole, (530 mg, 5.62 mmol) were dis-
solved in CH2Cl2 (750 mL), and purged with argon in a 1000 mL
flask before TFA (1–2 drops) was added as a catalyst and the mix-
ture was stirred overnight. The red solution was treated with p-
chloranil (526 mg, 2,147 mmol) stirred for 1 h, then Et3N (3 mL) and
BF3·Et2O (3 mL) were added. Immediately after the addition of
BF3·Et2O, bright-green fluorescence was observed. The organic
phase was separated, dried (Na2SO4), filtered, and concentrated.
The residue was purified by column chromatography (CH2Cl2); the
first green fluorescent fraction afforded the expected BODIPY chro-
Synthesis of BT2: The same procedure as that described for BT1
was applied, except twice as much 2 was used as a reagent to syn-
thesise BT2. Purification of the crude product by column chroma-
tography on silica gel (CH2Cl2) afforded compound BT2 (160 mg,
85%). 1H NMR (400 MHz, CDCl3): d=7.99 (s, 2H, triazole-H), 7.46–
7.44 (d, J=8.8 Hz, 4H), 7.19–7.17 (m, 5H), 7.14–7.11 (m, 20H), 7.06–
7.01 (m, 12H), 5.94 (s, 2H; pyrrole-H), 5.23 (s, 4H), 2.54 (s, 6H),
1.46 ppm (s, 6H); 13C NMR (100 MHz, CDCl3): d=160.4, 155.9, 144.2,
143.4, 143.3, 139.5, 137.1, 135.0, 132.9, 131.5, 131.4, 128.2, 128.1,
127.9, 127.1, 127.03, 126.98, 121.4, 121.2, 120.0, 107.8, 103.0, 62.3,
30.5, 14.4 ppm (overlapping was observed for some aromatic
carbon atoms); HRMS (MALDI-TOF): m/z calcd for [BT2+Na]+:
1201.48763; found: 1201.48530.
mophore
1
as an orange–red solid (158 mg, 22%). 1H NMR
(400 MHz, CDCl3): d=7.20–7.18 (d, J=8.8 Hz, 2H; ArH), 7.09–7.07
(d, d=8.8 Hz, 2H; ArH), 5.97 (s, 2H; pyrrole-H), 4.76–4.75 (d, d=
2.4 Hz, 2H), 4.70-4.69 (t, J=2.4 Hz, 1H), 2.55 (s, 6H), 1.42 ppm (s,
6H); 13C NMR (100 MHz, CDCl3): d=158.3, 155.4, 143.4, 129.4,
128.2, 121.4, 121.3, 119.1, 115.8, 76.1, 56.3, 46.9, 14.7 ppm; HRMS
(MALDI-TOF): m/z calcd for [1+H]+: 379.17933; found: 379.19998
Compound 2: The same procedure as that described for 1 was ap-
plied, except 3,5-bis(prop-2-yn-1-yloxy)benzaldehyde was used as
a reagent to synthesise BODIPY derivative 2. Purification of the
crude product by column chromatography on silica gel (CHCl3/
CH3OH (99/1, v/v)) afforded 2 (200 mg, 25%). 1H NMR (400 MHz,
CDCl3): d=6.70–6.69 (t, J=2.4 Hz, 1H), 6.59–6.58 (d, J=2.0 Hz, 2H),
5.98 (s, 2H, pyrrole-H), 4.69–4.68 (d, J=2.4 Hz, 4H), 2.55 (s, 6H),
2.50–2.49 (t, J=2.4 Hz, 2H), 1.54 ppm (s, 6H); 13C NMR (100 MHz,
CDCl3): d=159.6, 155.9, 143.3, 140.9, 136.9, 131.2, 121.4, 107.8,
103.9, 78.2, 76.2, 56.2, 14.8, 14.4 ppm; HRMS (MALDI-TOF): m/z
calcd for [2+H]+: 433.18989; found: 433.19510.
Synthesis of BT3: Compound BT3 was obtained from 3 with three
times the concentration of 3 in the same procedure as that used
for the synthesis of BT1. The crude product was purified by
column chromatography on silica gel (CH2Cl2) to yield BT3 as
1
a yellow solid (210 mg, 86%). H NMR (400 MHz, CDCl3): d=8.54 (s,
1H; triazole-H), 8.28 (s, 1H; triazole-H), 8.13 (s, 1H; triazole-H),
7.62–7.60 (d, J=8.8 Hz, 2H), 7.42–7.39 (m, 6H), 7.16–6.96 (m, 51H),
5.80 (s, 2H), 5.38 (s, 2H), 5.32 (s, 2H), 5.26 (s, 2H), 2.36 (s, 6H),
1.38 ppm (s, 6H); 13C NMR (100 MHz, CDCl3): d=155.6, 153.9, 150.1,
145.2, 144.7, 144.6, 144.5, 143.6, 143.52, 143.49, 143.44, 143.39,
142.9, 142.4, 142.3, 141.8, 139.8, 139.7, 139.6, 135.1, 132.9, 132.8,
132.7, 131.6, 131.50, 131.47, 131.45, 128.2, 128.10, 128.08, 128.06,
127.9, 127.13, 127.09, 127.04, 126.99, 126.93, 124.4, 122.1, 121.5,
121.2, 119.8, 119.7, 110.5, 67.5, 66.4, 63.7, 25.8, 14.4 ppm (overlap-
ping was observed for some aromatic carbon atoms); HRMS
(MALDI-TOF): m/z calcd for [BT3+H]+: 1607.67750; found:
1607.69337.
Compound 3: Following the same procedure as that used for the
synthesis of compound 1, but with 2,3,4-tris(prop-2-yn-1-yloxy)ben-
zaldehyde as an reagent, BODIPY derivative 3 was obtained. The
product was purified by column chromatography on silica gel
(CH2Cl2) to give 3 (180 mg, 20%). 1H NMR (400 MHz, CDCl3): d=
6.88–6.81 (dd, J=28 Hz, 2H; AB system), 5.89 (s, 2H; pyrrole-H),
4.77–4.76 (d, J=2.4 Hz, 2H), 4.75–4.74 (d, J=2.4 Hz, 2H), 4.66–4.65
(d, J=2.4 Hz, 2H), 2.50 (s; part of 6H for -CH3, part of 1H for
acetyl-H), 2.38–2.37 (t, J=2.4 Hz, 1H), 2.26–2.25 (t, J=2.4 Hz, 1H),
1.48 ppm (s, 6H); 13C NMR (100 MHz, CDCl3): d=155.5, 153.0, 149.6,
142.9, 141.1, 124.7, 122.9, 121.3, 111.0, 79.0, 78.0, 76.5, 76.0, 75.8,
61.1, 60.6, 57.3, 29.9, 14.8, 14.6 ppm; HRMS (MALDI-TOF): m/z calcd
for [3+H]+: 487.20045; found: 487.22620.
Synthesis of 7: Following the same procedure as that used for the
synthesis of BT1, with (prop-2-yn-1-yloxy)benzene as a reagent,
TPE derivative 7 was obtained. The product was purified by
column chromatography on silica gel (CH2Cl2/hexane (6:4)) to
1
afford 7 (66.0 mg, 84%). H NMR (400 MHz, CDCl3): d=7.96 (s, 1H;
triazole-H), 7.48–7.46 (d, J=8.0 Hz, 2H), 7.32–7.28 (m, 2H), 7.18–
7.16 (d, J=8.0 Hz, 2H), 7.13–7.10 (m, 9H), 7.04–6.96 (m, 9H),
5.28 ppm (s, 2H); 13C NMR (100 MHz, CDCl3): d=158.4, 145.2, 144.9,
143.42, 143.40, 143.3, 142.5, 139.6, 135.2, 132.9, 131.51, 131.48,
131.43, 129.8, 128.2, 128.1, 127.9, 127.1, 127.0, 126.9, 121.6, 120.9,
120.0, 115.0, 62.2 ppm (overlapping was observed for some aro-
matic carbon atoms); HRMS (MALDI-TOF): m/z calcd for [7+H]+:
506.22324; found: 506.23549.
Synthesis of BT1: Compounds 1 (60 mg, 0,157 mmol, 1.0 equiv)
and 5 (63.3 mg, 0,156 mmol, 1.1 equiv) were added to freshly dis-
tilled THF (50 mL). After 15 min, triethylamine (TEA; 10–30 mol%
per triple bond) was added to this mixture, and stirred for 10 min.
A mixture containing 10–30 mol% per triple bond of sodium ascor-
bate and 5–15 mol% of CuSO4·5H2O per triple bond (a stock solu-
tion of sodium ascorbate and CuSO4·5H2O in water prepared at
a concentration of 100 mgmLÀ1) was added to the reaction vessel.
Chem. Eur. J. 2016, 22, 736 – 745
743
ꢀ 2016 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim